References
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001;344:1031–7
- Bedi A, Zehnbauer BA, Barber JP, et al. Inhibition of apoptosis by BCR–ABL in chronic myeloid leukemia. Blood 1994;83:2038–44
- O'Hare T, Eide CA, Deininger MW. Bcr–Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–9
- Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–53
- de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–63
- Peggs K, Mackinnon S. Imatinib mesylate – the new gold standard for treatment of chronic myeloid leukemia. New Engl J Med 2003;348:1048–50
- Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401
- Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182–90
- Zheng S, Huang K-E, Pan Y-L, et al. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance. Gastric Cancer 2014;17:1–7
- Lindauer M, Hochhaus A. Dasatinib, in small molecules in oncology. Heidelberg, Berlin: Springer; 2014
- Gilbert JA. Dasatinib as first-line therapy for CML-CP. Lancet Oncol 2014;15:e7
- Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332–8
- Obr A, Roselova P, Grebenova D, Kuzelova K. Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin. PLoS One 2014;9:e107367
- Zhu Y, Pan L, Hong M, et al. The combination therapy of imatinib and dasatinib achieves longterm molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia. J Biomed Res 2014;28
- Wang Z, Sun W, Huang CK, et al. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm 2014. [Epub ahead of print]
- Wang L, Wang S, Chen M, et al. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. Drug Dev Ind Pharm 2014:1–6. [Epub ahead of print]
- Sun W, Wang Z, Chen H, et al. The effect of clopidogrel on pharmacokinetics of ivabradine and its metabolite in rats. Drug Dev Ind Pharm 2014:1–6. [Epub ahead of print]
- Wang L, Bao SH, Pan PP, et al. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm 2014:1–5. [Epub ahead of print]
- Lin G, Wang C, Qiu X, et al. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. Drug Dev Ind Pharm 2014;40:1616–22
- Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–94
- Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006;12:7180–6
- Zhang Q, Wen C, Xiang Z, et al. Determination of CUDC-101 in rat plasma by liquid chromatography mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal 2014;90:134–8
- Wen C, Lin C, Cai X, et al. Determination of sec-O-glucosylhamaudol in rat plasma by gradient elution liquid chromatography–mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2014;944:35–8
- Ma J, Lin C, Wen C, et al. Determination of bicuculline in rat plasma by liquid chromatography mass spectrometry and its application in a pharmacokinetic study. J Chromatogr B Anal Technol Biomed Life Sci 2014;953–954:143–6
- Ma J, Ding X, Sun C, et al. Development and validation a liquid chromatography mass spectrometry for determination of solasodine in rat plasma and its application to a pharmacokinetic study. J Chromatogr B Anal Technol Biomed Life Sci 2014;963:24–8
- Ma J, Cai J, Lin G, et al. Development of LC–MS determination method and back-propagation ANN pharmacokinetic model of corynoxeine in rat. J Chromatogr B Anal Technol Biomed Life Sci 2014;959:10–15
- Cai J, Lin C, Ma J, et al. Determination of rhynchophylline in rat plasma by liquid chromatography mass spectrometry and its application. J Chromatogr Sci 2014;52:661–5
- Wang X, Chen M, Wen C, et al. Determination of chidamide in rat plasma by LC–MS and its application to pharmacokinetics study. Biomed Chromatogr 2013;27:1801–6
- Zhou Y, Wang S, Ding T, et al. Evaluation of the effect of apatinib (YN968D1) on cytochrome P450 enzymes with cocktail probe drugs in rats by UPLC–MS/MS. J Chromatogr B Anal Technol Biomed Life Sci 2014;973C:68–75
- Gershkovich P, Ibrahim F, Sivak O, et al. A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. Drug Dev Ind Pharm 2014;40:338–44
- Meher JG, Yadav NP, Sahu JJ, Sinha P. Determination of required hydrophilic–lipophilic balance of citronella oil and development of stable cream formulation. Drug Dev Ind Pharm 2013;39:1540–6
- Graves RA, Ledet G, Nation CA, et al. An ultra-high performance chromatographic method for the determination of artemisinin. Drug Dev Ind Pharm 2014. [Epub ahead of print]
- Liu Y, Li X, Yang C, et al. UPLC–MS–MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. J Chromatogr Sci 2013;51:26–32
- Seong SJ, Lim M, Sohn SK, et al. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 2013;24:756–60
- Li X, He Y, Ruiz CH, et al. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 2009;37:1242–50
- Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582–91
- Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008;36:1357–64